Naveen Pemmaraju
University of Texas MD Anderson Cancer Center
801 Papers
1.6K Citations
Naveen Pemmaraju is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 45, co-authored 545 publications. Previous affiliations of Naveen Pemmaraju include University of Texas at Austin & King Saud University.
Chat about Author
Papers
Prospective Clinical Trials of Venetoclax and Hypomethylating Agents for Relapsed BPDCN
Naveen Pemmaraju,Luan Phan,Geoffrey Fell,Marlise R. Luskin,Mahesh Swaminathan,Sherry Pierce,C. Dinardo,Abhishek Maiti,Marina Y Konopleva,Andrew A. Lane +9 more
- 01 Mar 2025
Impact of SF3B1 mutation on outcomes in myelofibrosis.
Prithviraj Bose,Jayastu Senapati,Lucia Masarova,Naveen Pemmaraju,Guillermo Montalban-Bravo,Sherry Pierce,Lingsha Zhou,Guillermo Garcia-Manero,Hagop M. Kantarjian,Srdan Verstovsek +9 more
TL;DR: SF3B1 mutation is an uncommon event in myelofibrosis and does not substantially affect disease phenotype and outcomes, but MF pts with SF3B 1 mutation are more likely to be PRBC transfusion dependent.
Low-intensity chemotherapy (mini-HCVD) and ponatinib followed by blinatumomab (blina) and ponatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): A phase II study.
Lewis Nasr,Elias Jabbour,F. Haddad,Nicholas J. Short,W. Macaron,Maria das Graças Bichara Zoghbi,Ghayas C Issa,Musa Yilmaz,Naval Daver,Naveen Pemmaraju,Lucia Masarova,Farhad Ravandi,Nitin Jain,Wu Deen,Christopher R. Loiselle,Lourdes Waller,Glenda Banks,Rebecca Garris,Hagop M. Kantarjian +18 more
TL;DR: The combination of mini-HCVD and ponatinib 30mg daily in C1, with dose reduction to 15mg daily once in complete molecular response (CMR) was achieved by patients with newly diagnosed (ND), relapsed/refractory (R/R) or chronic myeloid leukemia in lymphoid blast phase (CML-LBP) as mentioned in this paper .
Outcomes of Chronic Myeloid Leukemia with No Major Molecular Response within 2 Years of Tyrosine Kinase Inhibitor Therapy
Aram H Bidikian,Hagop M. Kantarjian,Ghayas C Issa,Farhad Ravandi,Guillermo Garcia-Manero,Gautam Borthakur,Tapan M. Kadia,Naval Daver,Nitin Jain,Naveen Pemmaraju,Courtney D. DiNardo,F. Haddad,Sherry Pierce,Elias Jabbour,Koji Sasaki +14 more
TL;DR: In this article , the authors examined responses and outcomes associated with major molecular response (MMR) defined as BCR::ABL1 ≤ 0.1% IS after 2 years of treatment with tyrosine kinase inhibitors (TKI).
P495: phase 2 study of astx727 (decitabine/cedazuridine) plus venetoclax in patients with relapsed/refractory acute myeloid leukemia (aml) or previously untreated, elderly patients unfit for chemotherapy
T. Abuasab,Yesid Alvarado,Ghayas C Issa,Rubiul Islam,Nicholas J. Short,Musa Yilmaz,Nitin Jain,Lucia Masarova,S. Kornblau,Elias Jabbour,Naveen Pemmaraju,Guillermo Montalban-Bravo,Sherry Pierce,Courtney D. DiNardo,Tapan M. Kadia,Naval Daver,Marina Konopleva,Guillermo Garcia-Manero,Farhad Ravandi +18 more
TL;DR: In this paper , the authors investigated whether a total oral therapy regimen of ASTX727+venetoclax (ven) is feasible and safe for patients with relapsed/refractory AML (R/R) or pts with AML aged ≥ 75 or 18-74 with comorbid conditions prohibiting intensive chemotherapy were eligible to participate.